<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9100095</journal-id>
<journal-id journal-id-type="pubmed-jr-id">8509</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Cell Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Cell. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Molecular and cellular neurosciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1044-7431</issn>
<issn pub-type="epub">1095-9327</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27444126</article-id>
<article-id pub-id-type="pmc">5243932</article-id>
<article-id pub-id-type="doi">10.1016/j.mcn.2016.07.001</article-id>
<article-id pub-id-type="manuscript">NIHMS812008</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Cooper</surname>
<given-names>Daniel J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zunino</surname>
<given-names>Giulia</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bixby</surname>
<given-names>John L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lemmon</surname>
<given-names>Vance P.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami, 1400 NW 12th Ave, Miami, FL 33136, USA</aff>
<aff id="A2"><label>2</label>Center for Computational Science, University of Miami, 1400 NW 12th Ave, Miami, FL 33136, USA</aff>
<aff id="A3"><label>3</label>Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, 1400 NW 12th Ave, Miami, FL 33136, USA</aff>
<author-notes>
<corresp id="CR1">Co-Corresponding authors: Vance P. Lemmon, Ph.D., The Miami Project to Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136, USA, Phone +1 305 243 8184, Fax +1 305 243 3921, <email>vlemmon@med.miami.edu</email>, John L. Bixby, Ph.D., Professor of Molecular &amp; Cellular Pharmacology &amp; Neurological Surgery, Vice Provost for Research, University of Miami, DT 1205, Phone +1 305-243-7587, <email>jbixby@med.miami.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2018</year>
</pub-date>
<volume>80</volume>
<fpage>161</fpage>
<lpage>169</lpage>
<!--elocation-id from pubmed: 10.1016/j.mcn.2016.07.001-->
<abstract>
<p id="P1">High-throughput, target-based screening techniques have been utilized extensively for drug discovery in the past several decades. However, the need for more predictive <italic>in vitro</italic> models of <italic>in vivo</italic> disease states has generated a shift in strategy towards phenotype-based screens. Phenotype based screens are particularly valuable in studying complex conditions such as CNS injury and degenerative disease, as many factors can contribute to a specific cellular response. In this review, we will discuss different screening frameworks and their relative utility in examining mechanisms of neurodegeneration and axon regrowth, particularly in cell-based <italic>in vitro</italic> disease models.</p>
</abstract>
<kwd-group>
<kwd>high throughput screening</kwd>
<kwd>high content analysis</kwd>
<kwd>phenotypic analysis</kwd>
<kwd>axon growth</kwd>
<kwd>axon degeneration</kwd>
<kwd>axon regeneration</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>